152 related articles for article (PubMed ID: 20557086)
1. Formation and fate of a sulfenic acid intermediate in the metabolic activation of the antithrombotic prodrug prasugrel.
Dansette PM; Thébault S; Bertho G; Mansuy D
Chem Res Toxicol; 2010 Jul; 23(7):1268-74. PubMed ID: 20557086
[TBL] [Abstract][Full Text] [Related]
2. Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel.
Dansette PM; Libraire J; Bertho G; Mansuy D
Chem Res Toxicol; 2009 Feb; 22(2):369-73. PubMed ID: 19170597
[TBL] [Abstract][Full Text] [Related]
3. Thiolactone sulfoxides as new reactive metabolites acting as bis-electrophiles: implication in clopidogrel and prasugrel bioactivation.
Dansette PM; Levent D; Hessani A; Bertho G; Mansuy D
Chem Res Toxicol; 2013 May; 26(5):794-802. PubMed ID: 23527615
[TBL] [Abstract][Full Text] [Related]
4. Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring.
Dansette PM; Rosi J; Debernardi J; Bertho G; Mansuy D
Chem Res Toxicol; 2012 May; 25(5):1058-65. PubMed ID: 22482514
[TBL] [Abstract][Full Text] [Related]
5. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Takahashi M; Kurihara A; Okazaki O; Farid NA; Ikeda T
Xenobiotica; 2009 Mar; 39(3):218-26. PubMed ID: 19280520
[TBL] [Abstract][Full Text] [Related]
6. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
Hagihara K; Kazui M; Kurihara A; Yoshiike M; Honda K; Okazaki O; Farid NA; Ikeda T
Drug Metab Dispos; 2009 Nov; 37(11):2145-52. PubMed ID: 19704027
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite.
Hagihara K; Kazui M; Kurihara A; Iwabuchi H; Ishikawa M; Kobayashi H; Tanaka N; Okazaki O; Farid NA; Ikeda T
Drug Metab Dispos; 2010 Jun; 38(6):898-904. PubMed ID: 20228231
[TBL] [Abstract][Full Text] [Related]
8. In vitro biotransformation studies of 2-oxo-clopidogrel: multiple thiolactone ring-opening pathways further attenuate prodrug activation.
Zhu Y; Zhou J
Chem Res Toxicol; 2013 Jan; 26(1):179-90. PubMed ID: 23249383
[TBL] [Abstract][Full Text] [Related]
9. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer.
Dansette PM; Rosi J; Bertho G; Mansuy D
Chem Res Toxicol; 2012 Feb; 25(2):348-56. PubMed ID: 22103858
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic studies on the metabolic scission of thiazolidinedione derivatives to acyclic thiols.
Reddy VB; Karanam BV; Gruber WL; Wallace MA; Vincent SH; Franklin RB; Baillie TA
Chem Res Toxicol; 2005 May; 18(5):880-8. PubMed ID: 15892582
[TBL] [Abstract][Full Text] [Related]
11. Bioactivation of clopidogrel and prasugrel: factors determining the stereochemistry of the thiol metabolite double bond.
Dansette PM; Levent D; Hessani A; Mansuy D
Chem Res Toxicol; 2015 Jun; 28(6):1338-45. PubMed ID: 25970225
[TBL] [Abstract][Full Text] [Related]
12. The intestine as an important contributor to prasugrel active metabolite formation in vivo.
Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Izumi T; Ikeda T; Kurihara A
Drug Metab Dispos; 2011 Apr; 39(4):565-70. PubMed ID: 21189331
[TBL] [Abstract][Full Text] [Related]
13. Thiophene sulfoxides as reactive metabolites: formation upon microsomal oxidation of a 3-aroylthiophene and fate in the presence of nucleophiles in vitro and in vivo.
Valadon P; Dansette PM; Girault JP; Amar C; Mansuy D
Chem Res Toxicol; 1996 Dec; 9(8):1403-13. PubMed ID: 8951246
[TBL] [Abstract][Full Text] [Related]
14. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4.
Sahali-Sahly Y; Balani SK; Lin JH; Baillie TA
Chem Res Toxicol; 1996 Sep; 9(6):1007-12. PubMed ID: 8870989
[TBL] [Abstract][Full Text] [Related]
15. First evidence that cytochrome P450 may catalyze both S-oxidation and epoxidation of thiophene derivatives.
Dansette PM; Bertho G; Mansuy D
Biochem Biophys Res Commun; 2005 Dec; 338(1):450-5. PubMed ID: 16137656
[TBL] [Abstract][Full Text] [Related]
16. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.
Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS
Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785
[TBL] [Abstract][Full Text] [Related]
17. Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel.
Hagihara K; Kazui M; Kurihara A; Kubota K; Ikeda T
Drug Metab Dispos; 2011 Feb; 39(2):208-14. PubMed ID: 21036950
[TBL] [Abstract][Full Text] [Related]
18. Disposition and metabolic fate of prasugrel in mice, rats, and dogs.
Smith RL; Gillespie TA; Rash TJ; Kurihara A; Farid NA
Xenobiotica; 2007 Aug; 37(8):884-901. PubMed ID: 17701835
[TBL] [Abstract][Full Text] [Related]
19. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved.
He K; Talaat RE; Pool WF; Reily MD; Reed JE; Bridges AJ; Woolf TF
Drug Metab Dispos; 2004 Jun; 32(6):639-46. PubMed ID: 15155556
[TBL] [Abstract][Full Text] [Related]
20. Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite.
Carballal S; Radi R; Kirk MC; Barnes S; Freeman BA; Alvarez B
Biochemistry; 2003 Aug; 42(33):9906-14. PubMed ID: 12924939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
